IRMD Stock Analysis: Buy, Sell, or Hold?
IRMD - iRadimed Corporation
$86.89
1.62 (1.90%)
▲
5d:
+0.17%
30d:
-6.62%
90d:
-12.97%
BUY
HIGH Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 04, 2026
0d
Smart Money Distribution
IRMD is up 3.0% this week, but smart money is buying puts. Top strike: $85 2026-06-18 with 14 OI. Put ratio: 84% View Scanner →
Strength: 4.9/10
Get Alerted When IRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IRMD appears deeply undervalued. Market expects -5.6% annual earnings decline despite 22% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: IRMD appears deeply undervalued. Market expects -5.6% annual earnings decline despite 22% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$89.34
Based on 8.8% avg growth
INTRINSIC VALUE TODAY
$55.47
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRMD is currently trading at $86.89, which is considered slightly low relative to its 30-day fair value range of $85.22 to $93.41. From a valuation perspective, the stock is trading at a discount (Forward PE: 36.2) compared to its historical average (43.0). Remarkably, the market is currently pricing in an annual earnings decline of 5.6% over the next few years. This pessimistic expectation contrasts with the company's recent 22.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRMD is in a strong downtrend. The price is approaching resistance at $88.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $118.00 (+38.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRMD is in a strong downtrend. The price is approaching resistance at $88.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $118.00 (+38.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$85.22 -
$93.41
Company Quality Score
58/100
(HOLD)
Options IV Signal
16th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 16th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.4% below Wall St target ($118.00)
Trading Range Analysis
30-Day Trading Range
$85.22 -
$93.41
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$4.76
(5.5%)
Support & Resistance Levels
Support Level
$76.95
Resistance Level
$88.72
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
36.21
Wall Street Target
$118.00
(+38.4%)
Revenue Growth (YoY)
12.6%
Earnings Growth (YoY)
22.1%
Profit Margin
27.4%
Valuation Discount vs History
-5.6% cheaper
PE vs Historical
36.2 vs 43.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.6%
(market-implied from PE analysis)
1-Year Target
$80.49
(-6%)
2-Year Target
$75.99
(-11%)
3-Year Target
$71.73
(-16%)
3-Yr Target (if PE normalizes)
(PE: 36→43)
$85.19
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 36.2, Growth: 13.5%)
$124.66
(+46%)
Base:
(SPY PE: 22.0, Growth: 13.5%)
$75.88
(-11%)
Bear:
(PE: 18.7, Growth: 13.5%)
$64.50
(-24%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (36x PE) as earnings recover.
Trailing PE: 46.08 | Current EPS (TTM): $1.83
Bull Case
$119.36
(+40%)
Analyst growth 28.7%, PE expands to 50.7
Base Case
$108.51
(+27%)
Market implied 28.7%, PE stable at 46.1
Bear Case
$57.34
(-33%)
Severe decline -20.0%, PE contracts to 39.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 36.2 to 43.0
Stabilization Target:
$101.26
(+18.8%)
PE Expansion Potential:
+18.8%
Share & Embed Analysis
Last updated: May 14, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger E Susi
SELL
2500 shares
2026-04-21
Roger E Susi
SELL
5000 shares
2026-04-20
Roger E Susi
SELL
2500 shares
2026-04-14
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$85 | 55 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$84 | 60 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 62 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 53 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 52 HOLD |
Advanced IRMD Option Strategies
Professional options setups generated by AI based on today's IRMD price and gamma walls.
